MedPath

Levonorgestrel

Generic Name
Levonorgestrel
Brand Names
Afirmelle 28 Day, Aftera, Alesse, Altavera 28 Day, Amethia 91 Day, Amethyst, Ashlyna 91 Day, Aubra 28 Day, Aviane 28, Ayuna 28 Day Pack, Balcoltra 28 Day, Bionafem, Camrese 91 Day, Camreselo 91 Day, Chateal 28 Day, Climara Pro, Curae, Daysee 91 Day, Delyla 28 Day, Dolishale 28 Day, Econtra, Enpresse 28 Day, Fallback Solo, Falmina 28 Day, Fayosim 91 Day, Her Style, Iclevia 91 Day, Indayo, Introvale 91 Day, Jaimiess 91 Day, Jolessa 91 Day, Joyeaux 28 Day, Kurvelo, Kyleena, Larissia 28 Day Pack, Levonest 28 Day, Levora 0.15/30 28 Day, Liletta, Lillow 28 Day, Lo Simpesse, LoJaimiess, Loseasonique, Lutera 28 Day, Marlissa 28 Day, Min-ovral, Mirena, Morning After, My Choice, My Way, Myzilra 28 Day, New Day, Next Choice, Next Choice One Dose, Opcicon One-step, Option 2, Orsythia 28 Day, Plan B, Plan B One-step, Portia 28 Day, Preventeza, Quartette 91 Day Pack, React, Rivelsa 91 Day, Seasonale, Seasonique, Setlakin 91 Day, Simpesse, Skyla, Sronyx 28 Day, Take Action, Triquilar, Trivora 28 Day, Twirla 3 Count Weekly Patch, Tyblume 28 Day, Vienva 28 Day
Drug Type
Small Molecule
Chemical Formula
C21H28O2
CAS Number
797-63-7
Unique Ingredient Identifier
5W7SIA7YZW
Background

Levonorgestrel (LNG) is a synthetic progestogen similar to Progesterone used in contraception and hormone therapy. Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of these devices are known as Jaydess, Kyleena, and Mirena. A subdermal implant of levonorgestrel that slowly releases the hormone over a long-term period is also available. In addition to the above uses, levonorgestrel is used as a component of long-term combination contraceptives.

Globally, levonorgestrel is the most commonly used emergency contraceptive. It was initially granted FDA approval in 1982 and was the first emergency contraceptive containing only progesterone, showing high levels of efficacy and a lack of estrogenic adverse effects when compared to older emergency contraceptive regimens.

Indication

Emergency contraception

Levonorgestrel, in the single-agent emergency contraceptive form, is indicated for the prevention of pregnancy after the confirmed or suspected failure of contraception methods or following unprotected intercourse. It is distributed by prescription for patients under 17, and over the counter for those above this age. This levonorgestrel-only form of contraception is not indicated for regular contraception and must be taken as soon as possible within 72 hours after intercourse. It has shown a lower efficacy when it is used off label within 96 hours.

Long-term contraception or nonemergency contraception

In addition to the above indication in emergency contraception, levonorgestrel is combined with other contraceptives in contraceptive formulations designed for regular use, for example with ethinyl estradiol. It is used in various hormone-releasing intrauterine devices for long-term contraception ranging for a duration of 3-5 years. Product labeling for Mirena specifically mentions that it is recommended in women who have had at least 1 child and can be indicated for the prevention of pregnancy for up to 8 years. A subdermal implant is also available for the prevention of pregnancy for up to 5 years.

Hormone therapy and off-label uses

Levonorgestrel is prescribed in combination with estradiol as hormone therapy during menopause to manage vasomotor symptoms and to prevent osteoporosis.Off-label, levonorgestrel may be used to treat menorrhagia, endometrial hyperplasia, and endometriosis.

Associated Conditions
Endometrial Hyperplasia, Endometriosis, Heavy Menstrual Bleeding, Hypermenorrhea, Postmenopausal Osteoporosis, Pregnancy, Moderate Menopausal Vasomotor Symptoms, Severe Vasomotor Symptoms Associated With Menopause
Associated Therapies
Emergency Contraception

Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception

Phase 3
Not yet recruiting
Conditions
Contraception
Interventions
First Posted Date
2024-12-11
Last Posted Date
2024-12-27
Lead Sponsor
The University of Hong Kong
Target Recruit Count
980
Registration Number
NCT06727734

The Effect of Levonorgestrel Intrauterine System in Preventing Endometrial Polyps Recurrence

Not Applicable
Not yet recruiting
Conditions
Endometrial Polyp
Interventions
First Posted Date
2024-10-01
Last Posted Date
2024-10-04
Lead Sponsor
Zhang Jian
Target Recruit Count
558
Registration Number
NCT06620939

A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause

Phase 1
Active, not recruiting
Conditions
Diabetes Mellitus, Type 2
Interventions
First Posted Date
2024-07-22
Last Posted Date
2025-03-25
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
37
Registration Number
NCT06513104
Locations
🇩🇪

Parexel International GmbH, Berlin, Germany

Assessing the Efficacy and Acceptability of Two Missed Period Pills Regimens

Phase 2
Not yet recruiting
Conditions
Pregnancy Related
Pregnancy Early
Interventions
First Posted Date
2024-07-09
Last Posted Date
2024-07-18
Lead Sponsor
Gynuity Health Projects
Target Recruit Count
286
Registration Number
NCT06492889

A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant

Phase 1
Completed
Conditions
Obesity
Interventions
First Posted Date
2024-06-14
Last Posted Date
2025-05-08
Lead Sponsor
Novo Nordisk A/S
Target Recruit Count
43
Registration Number
NCT06461039
Locations
🇨🇦

Altasciences Clinical Company, Inc, Montreal, Quebec, Canada

Phase II Study of Ovulation in Obese Women

Phase 2
Recruiting
Conditions
Pregnancy Prevention
Interventions
First Posted Date
2024-03-12
Last Posted Date
2024-03-12
Lead Sponsor
InnovaGyn, Inc.
Target Recruit Count
22
Registration Number
NCT06306131
Locations
🇺🇸

Carolina Women's Research and Wellness Center, Raleigh, North Carolina, United States

Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium

Phase 2
Not yet recruiting
Conditions
Endometrial Cancer
Atypical Hyperplasia
Interventions
First Posted Date
2023-10-10
Last Posted Date
2025-04-22
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
71
Registration Number
NCT06073184

Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine

First Posted Date
2023-10-06
Last Posted Date
2024-05-16
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
60
Registration Number
NCT06071442
Locations
🇺🇸

Research Site, Brooklyn, Maryland, United States

Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study

Not yet recruiting
Conditions
Bleeding Disorder
Heavy Menstrual Bleeding
Von Willebrand Diseases
Interventions
First Posted Date
2023-06-23
Last Posted Date
2023-06-23
Lead Sponsor
Oregon Health and Science University
Target Recruit Count
300
Registration Number
NCT05916469

Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days

Phase 2
Recruiting
Conditions
Pregnancy Prevention
Interventions
First Posted Date
2023-01-25
Last Posted Date
2024-03-12
Lead Sponsor
InnovaGyn, Inc.
Target Recruit Count
21
Registration Number
NCT05695352
Locations
🇺🇸

Carolina Women's Research and Wellness Center, Raleigh, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath